A phase II pilot study of the efficacy and safety of nivolumab and ipilimumab in T1aN0M0 renal cell carcinoma patients ineligible for surgical treatment.

Ilya Tsimafeyeu,Maria Volkova,Rustem Gafanov,Dmitry Nosov,Axel Bex

A phase II pilot study of the efficacy and safety of nivolumab and ipilimumab in T1aN0M0 renal cell carcinoma patients ineligible for surgical treatment.

2020

Ilya Tsimafeyeu
Maria Volkova
Rustem Gafanov
Dmitry Nosov
Axel Bex

TPS769Background: Surgery remains the standard curative-intent therapy for localized renal cell carcinoma (RCC). Thus, systemic therapy for RCC should only be considered in patients who have contra...

Keywords:

Pathology
Oncology
Ipilimumab
Nivolumab
Internal medicine
Renal cell carcinoma
Medicine
in patient
surgical treatment
Systemic therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations